A Multicenter, Randomized, Open Label, Parallel-group Phase IIB Study on the Efficacy and Safety of Oral Regimens of DEB025 Alone or in Combination With Ribavirin Versus Standard of Care (Peg-IFNalpha2a Plus Ribavirin) in Treatment-naïve Hepatitis C Genotype 2 and 3 Patients. - NIL

Trial Profile

A Multicenter, Randomized, Open Label, Parallel-group Phase IIB Study on the Efficacy and Safety of Oral Regimens of DEB025 Alone or in Combination With Ribavirin Versus Standard of Care (Peg-IFNalpha2a Plus Ribavirin) in Treatment-naïve Hepatitis C Genotype 2 and 3 Patients. - NIL

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs Alisporivir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms VITAL-1
  • Sponsors Novartis
  • Most Recent Events

    • 27 Jun 2015 Results published in the Hepatology.
    • 31 Jul 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
    • 19 Apr 2012 Results presented at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL-2012).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top